"Bevacizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF RECEPTORS and helps prevent the proliferation of blood vessels.
| Descriptor ID |
D000068258
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.375 D12.776.124.790.651.114.224.060.438 D12.776.377.715.548.114.224.200.438
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bevacizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Bevacizumab [D12.776.124.486.485.114.224.060.375]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Bevacizumab [D12.776.124.790.651.114.224.060.438]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Bevacizumab [D12.776.377.715.548.114.224.200.438]
Below are MeSH descriptors whose meaning is more specific than "Bevacizumab".
This graph shows the total number of publications written about "Bevacizumab" by people in this website by year, and whether "Bevacizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 3 | 4 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bevacizumab" by people in Profiles.
-
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2023 Feb 20; 41(6):1285-1295.
-
Intravitreal injections of anti-VEGF agents during COVID-19 pandemic: clinical audit from Tanta University Hospital. Int Ophthalmol. 2021 Apr; 41(4):1437-1443.
-
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. Laryngoscope. 2021 06; 131(6):E1941-E1949.
-
Combination Therapy by Tissue-Specific Suicide Gene and Bevacizumab in Intramedullary Spinal Cord Tumor. Yonsei Med J. 2020 Dec; 61(12):1042-1049.
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
-
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 12 01; 6(12):1939-1946.
-
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020 10 14; 22(10):1505-1515.
-
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019 10; 20(10):1360-1369.
-
Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report. Neuroradiol J. 2019 Oct; 32(5):317-327.
-
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.